Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ID-LV305 |
Synonyms | |
Therapy Description |
ID-LV305 is a modified lentiviral vector encoding human tumor-associated cancer-testis antigen (NY-ESO-1) which may stimulates immune response against NY-ESO-1-expressing tumor cells (PMID: 31227504). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ID-LV305 | LV305 | ID-LV305 is a modified lentiviral vector encoding human tumor-associated cancer-testis antigen (NY-ESO-1) which may stimulates immune response against NY-ESO-1-expressing tumor cells (PMID: 31227504). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |